Skip to product content

ACTIVE PHARMACEUTICAL INGREDIENT

Azithromycin API

Research Azithromycin API through FDA DMF and China CDE records. Compare reported holders, registration numbers and status definitions, then subscribe to search and export complete available data.

Complete data requires an active subscription. Already subscribed? Sign in to access your data.

The chemical profile identifies the parent compound, CAS 83905-01-5. Records are selected by reported name; an unspecified hydration state does not establish anhydrous material. Explicit hydrates, salts, finished dosage forms and intermediates are excluded. Unresolved N and FORM I subjects are also excluded.

Azithromycin registration data overview

This overview includes 6 FDA API DMF records and 33 CDE API registrations for Azithromycin (CAS 83905-01-5), selected by reported substance name. FDA and CDE status counts follow each registry’s own definitions.

0 documented company-name correspondences

The registries have different snapshot dates. Record counts do not represent qualified or available suppliers. Azithromycin records without a stated hydration state do not establish anhydrous material. A lack of documented company-name correspondences does not establish that no companies appear in both registries.

Personal API data subscription

$19.00 per month

$149.00 per year

Billed $149.00 every year

This profile: 6 FDA DMF records, 33 CDE registrations and 0 company-name correspondences.

Subscription benefits and CSV samples
  • Complete available registry records
  • Search and status filters
  • Documented company-name correspondences
  • CSV exports with sources

One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.

Reported companies in Azithromycin registry records

Start an Azithromycin supplier search with the reported names in each market. No cross-registry company-name correspondences are documented for this profile. Similar names, translations and membership of the same corporate group do not prove an identical legal entity or manufacturing site.

Free previewShowing 0 sample records of 0.

0 company-name correspondences

No exact company-name correspondences are documented for these snapshots.

Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.

Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.

US REGULATORY RECORDS

Azithromycin FDA Drug Master Files

Compare the original Azithromycin subjects, holder names, submission dates and activity status. The selection includes an explicit anhydrous subject and API subjects without a stated hydration state; consult the holder for the actual material form.

6 API DMF records · 5 distinct reported holder names

4Active (A)

2Inactive (I)

A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.

Free previewShowing 3 sample records of 6.

  • WOCKHARDT LTDDMF number 14480Inactive (I)Record details
    DMF number
    14480
    Activity status
    Inactive (I)
    DMF type
    II
    Initial submission
    1999-10-14
    Reported holder
    WOCKHARDT LTD
    Reported subject
    AZITHROMYCIN USP
  • WOCKHARDT LTDDMF number 18073Active (A)Record details
    DMF number
    18073
    Activity status
    Active (A)
    DMF type
    II
    Initial submission
    2005-02-11
    Reported holder
    WOCKHARDT LTD
    Reported subject
    ANHYDROUS AZITHROMYCIN
  • SHIJIAZHUANG PHARMACEUTICAL GROUP HUASHENG PHARMA CO LTDDMF number 20074Inactive (I)Record details
    DMF number
    20074
    Activity status
    Inactive (I)
    DMF type
    II
    Initial submission
    2006-12-18
    Reported holder
    SHIJIAZHUANG PHARMACEUTICAL GROUP HUASHENG PHARMA CO LTD
    Reported subject
    AZITHROMYCIN USP (API)

Free preview

More records available with a subscription: 3.

Inclusion criteria
  • Includes 6 Type II Azithromycin API records: unqualified, USP, USP (API), explicitly anhydrous and lyophilized bulk sterile subjects. Lyophilization and USP wording do not independently establish hydration state.
  • Excludes explicit monohydrate, dihydrate and hydrogencitrate subjects, facility descriptions, oral-suspension and taste-masking granules, and the amine drug-substance intermediate. The source spellings AZITHROMICIN and MONHYDRATE are screened as related candidates.
  • DMF 15985 (AZITHROMYCIN N) and DMF 16268 (AZITHROMYCIN-FORM I) are excluded because their chemical identities are unresolved in the supplied list. No hydrate or polymorph assignment is inferred from those qualifiers.
  • An unqualified Azithromycin subject does not establish anhydrous material. Original holder and subject spelling, whitespace and individual DMF numbers are retained; Excel submission dates are converted to ISO dates. One holder can have several records.

CHINA REGULATORY RECORDS

Azithromycin NMPA CDE registrations

Compare Azithromycin API registrations reported as 阿奇霉素, including original company names, addresses, packaging and joint-review identifiers. The reported substance name does not specify hydration state.

33 name-selected API registration records

30Approved or qualifying prior approval (A)

3Technical review not passed or unlinked (I)

CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.

Free previewShowing 3 sample records of 33.

  • 河北国龙制药有限公司Registration number Y20170000182Approved or qualifying prior approval (A)Record details
    Registration number
    Y20170000182
    Reported substance name
    阿奇霉素
    Reported company names
    河北国龙制药有限公司
    Reported company addresses
    河北省石家庄经济技术开发区兴业街9号
    Reported product origin
    Domestic (国产)
    Reported packaging
    25Kg/袋
    Reported specification
    Not provided by source
    Record updated
    2024-10-24
    Joint review status
    Approved or qualifying prior approval (A)
    Reported validity date
    2028-05-03
    Source remarks
    CYHS1200290
  • PLIVA Croatia Ltd.;PLIVA Croatia Ltd.;广州安信医药有限公司Registration number Y20180001512Technical review not passed or unlinked (I)Record details
    Registration number
    Y20180001512
    Reported substance name
    阿奇霉素
    Reported company names
    PLIVA Croatia Ltd.;PLIVA Croatia Ltd.;广州安信医药有限公司
    Reported company addresses
    Prilaz baruna Filipovica 25, Zagreb, Croatia;Prudnicka cesta 54, Croatia-10291 Prigorje Brdovecko;广州高新技术产业开发区科学城揽月路80号科技创新基地D区第6层614-616单元
    Reported product origin
    Imported (进口)
    Reported packaging
    25kg/桶
    Reported specification
    Not provided by source
    Record updated
    2019-02-03
    Joint review status
    Technical review not passed or unlinked (I)
    Reported validity date
    Not provided by source
    Source remarks
    Not provided by source
  • 湖南九典宏阳制药有限公司Registration number Y20180001793Approved or qualifying prior approval (A)Record details
    Registration number
    Y20180001793
    Reported substance name
    阿奇霉素
    Reported company names
    湖南九典宏阳制药有限公司
    Reported company addresses
    湖南省望城经济技术开发区铜官循环经济工业基地
    Reported product origin
    Domestic (国产)
    Reported packaging
    10kg/桶、25kg/桶
    Reported specification
    Not provided by source
    Record updated
    2023-10-17
    Joint review status
    Approved or qualifying prior approval (A)
    Reported validity date
    2028-10-10
    Source remarks
    CYHT1600333

Free preview

More records available with a subscription: 30.

Inclusion criteria
  • Includes 33 entries whose reported substance name is exactly 阿奇霉素. The name does not establish anhydrous material or verify CAS 83905-01-5 for every registration.
  • Excludes the 13 related registrations explicitly naming aspartate, lactobionate, maleate, hydrochloride, sulfate, disodium hydrogen citrate, fumarate or disodium hydrogen phosphate forms.
  • All eleven source columns and original row order are retained. Blank fields remain blank and are displayed as Not provided by source. Semicolon-separated names and addresses, repeated parties, dates and approval references are preserved without inferring roles or current validity.

Azithromycin identity and molecular structure

Azithromycin is a macrolide antibiotic identified here by CAS 83905-01-5 and ChEBI CHEBI:2955. The formula and structure describe the parent molecule without water of crystallization. USP distinguishes anhydrous, monohydrate and dihydrate forms. A registry subject that simply says Azithromycin does not verify the physical form supplied by a manufacturer.

Azithromycin — 2D chemical structure

Loading molecular structure…

Open structure in ChEBI
CAS number
83905-01-5
ChEBI: AzithromycinUSP: Azithromycin chemical forms

Parent compound identity; not a CAS assignment verified individually for every registry record.

ChEBI identifier
CHEBI:2955
ChEBI: Azithromycin
InChIKey
MQTOSJVFKKJCRP-BICOPXKESA-N
ChEBI: Azithromycin

Azithromycin chemical properties

Use these parent-compound identifiers to compare chemical references. Azithromycin monohydrate and dihydrate have separate CAS numbers and contain one and two waters of crystallization respectively. Confirm hydration state, assay basis and the applicable specification with the manufacturer before comparing materials.

Molecular formula
C38H72N2O12
ChEBI: Azithromycin
Average molecular mass
748.996 g/mol
ChEBI: Azithromycin

Average mass reported by ChEBI for the parent compound; not a batch assay or specification.

Monoisotopic mass
748.50853 Da
ChEBI: Azithromycin

Chemical-form and regulatory resources

Use these official Azithromycin references to check substance identity and interpret the scope of the registration records.

Azithromycin API sourcing questions

What chemical identity does this Azithromycin page cover?

The chemical profile covers Azithromycin, CAS 83905-01-5, with molecular formula C38H72N2O12. Its structure represents the parent compound. Registration tables are selected by reported substance names, so they do not confirm that every listed material is anhydrous.

Is Azithromycin the same as its monohydrate or dihydrate?

Azithromycin monohydrate has CAS 121470-24-4 and contains one water of crystallization; the dihydrate has CAS 117772-70-0 and contains two. The anhydrous identity has CAS 83905-01-5. USP describes all three forms in its monograph preview, so a USP subject alone does not identify hydration state. Explicit hydrate subjects are excluded here.

Which FDA Azithromycin records are included?

The FDA snapshot contains 6 Type II Azithromycin API records selected from unqualified, USP, USP (API), anhydrous and lyophilized bulk sterile subjects. Type II also covers intermediates and drug products, so the type alone is insufficient. Explicit hydrates, salts, facilities, granules and an amine intermediate are excluded.

Why are Azithromycin N and FORM I excluded?

DMF 15985 reports AZITHROMYCIN N and DMF 16268 reports AZITHROMYCIN-FORM I. The supplied list does not resolve their chemical identities or hydration states. They are excluded pending substance-level evidence rather than assigned to CAS 83905-01-5. These qualifiers are not treated as verified synonyms of the parent compound.

Does an active Azithromycin DMF mean the supplier is FDA approved?

No. A and I indicate active and inactive DMFs. FDA states that DMFs are neither approved nor disapproved; technical contents are reviewed with applications that reference them. An Azithromycin DMF number does not establish manufacturing-site qualification, access to a dossier, current supply or suitability for a particular application.

What do the CDE A and I identifiers mean?

For these Azithromycin registrations, A and I describe Chinese review status independently of FDA activity. A can result from joint review with an approved formulation, transfer of qualifying prior approvals or an independent API review. I identifies material that has not passed technical review or has not been linked to a formulation registration. Check the current official entry before relying on its status.

Why are only 阿奇霉素 registrations included?

The CDE selection contains 33 records named exactly 阿奇霉素. Related salt forms have different substance names and are excluded from this Azithromycin parent-compound profile. The Chinese name alone does not verify water content, a particular crystalline form or a manufacturer specification.

How should I compare companies before sourcing Azithromycin API?

Use the registry number to locate the original entry, then ask the company to confirm its legal name, manufacturing site, chemical form, specification and applicable regulatory documentation. A CDE company field can list multiple parties. This page does not infer their roles from order or equate translated names with an FDA holder.

What Azithromycin data can I preview and export?

Review free Azithromycin samples and download their sample CSV files before subscribing. An active personal subscription provides the complete available records for this profile, with search, status filters and CSV exports. It does not provide quotations, supplier qualification or live registry monitoring.

ChEBI: AzithromycinUSP: Azithromycin chemical formsFDA DMF list: Q2 2026 snapshotNMPA CDE API registryFDA: Types of Drug Master FilesFDA: Drug Master FilesChina API registration status explained

Data sources

Official references for chemical identity, registration records and status definitions. Open the original source to check current information.

ChEBI: Azithromycin

Open official source

EMBL-EBI

Parent-compound CAS, molecular formula, calculated masses, InChIKey and stereochemical SMILES.

View citation evidence

“C38H72N2O12”

EMBL-EBI

Molecular formula reported in the ChEBI entry CHEBI:2955.

USP: Azithromycin chemical forms

Open official source

United States Pharmacopeia

The public monograph preview distinguishes anhydrous, monohydrate and dihydrate identities. It is used for chemical-form identification, not as a current batch specification.

View citation evidence

“Azithromycin is anhydrous or contains 1 or 2 molecules of water of hydration.”

United States Pharmacopeia

Definition in the USP-NF Azithromycin monograph preview, cited there as 2023; the preview is not evidence that a listed material meets a current monograph.

FDA DMF list: Q2 2026 snapshot

Open official source

U.S. Food and Drug Administration

The records displayed here use the second-quarter snapshot, with a June 30, 2026 cutoff. The official page may offer a later quarterly list.

View citation evidence

“A=active ; I=inactive”

U.S. Food and Drug Administration

FDA activity-status legend; the snapshot date applies to the records shown here.

FDA: Drug Master Files

Open official source

U.S. Food and Drug Administration

FDA explains how DMFs support applications that reference their technical contents.

View citation evidence

“Are neither approved nor disapproved.”

U.S. Food and Drug Administration

FDA statement about DMFs; active status is not product approval.

FDA: Types of Drug Master Files

Open official source

U.S. Food and Drug Administration

Type II covers drug substances, intermediates, preparation materials and drug products; a subject-level screen is needed to select API records.

View citation evidence

“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”

U.S. Food and Drug Administration

FDA definition of Type II; the category is broader than API-only filings.

NMPA CDE API registry

Open official source

Center for Drug Evaluation, National Medical Products Administration

The October 5, 2026 snapshot contains the reported names, company fields and registration information used here.

View citation evidence

“阿奇霉素”

Center for Drug Evaluation, National Medical Products Administration

Original substance name in the CDE snapshot; the name alone does not specify hydration state.

China API registration status explained

Open official source

Liaoning Medical Products Administration

Official explanation of the A and I identifiers, including the different routes by which a record can receive A status.

View citation evidence

“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”

Liaoning Medical Products Administration

The regulator explains I as material that has not passed technical review or has not been linked to a formulation registration.

Continue your Azithromycin API research

Compare Azithromycin registry names, statuses and chemical-form boundaries using the free samples. Subscribe to search, filter and export the complete available FDA and CDE records for your sourcing review.

Complete data requires an active subscription. Already subscribed? Sign in to access your data.

Report a data issue

Report an Azithromycin data issue with the page address, registry number and supporting official source. APIRFQ support handles data corrections; contact the relevant company separately about material specifications or supply.

Contact data support